Alpha Tau Medical logo

Alpha Tau Medical

DRTS | NASDAQ
Chart Builder DCF Calculator
$11.97
-$1.41 (-10.54%)
At close: Nov 16, 2026, 4:00 PM ET
$12.00
+$0.03 (+0.25%)
After-hours: Nov 16, 2026, 7:52 PM ET
-10.54%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
26
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #901/1021 (Top 88%)

Key Statistics

Market Data

Market Cap $1.11B
1D Range
11.81 14.41
52W Range
3.47 15.50

Valuation (TTM)

PE -11.51
PB 25.13
EV/EBITDA -20.82

Valuation (NTM)

Forward PE N/A
Forward PEG -0.14
Price Target $16.00
Loading financial charts...

Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the t...

Sector Healthcare
Industry Biotechnology
Employees 121
IPO Date Mar 8, 2021
Fiscal Year January - December

Latest News

Alpha Tau Medical Ltd. (DRTS) Discusses REGAIN Study Interim Results for Recurrent Glioblastoma Transcript

11 hours ago · seekingalpha.com

Alpha Tau Medical Ltd. (DRTS) Discusses REGAIN Study Interim Results for Recurrent Glioblastoma Transcript
Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients

16 hours ago · benzinga.com

Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients
Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16

1 day ago · globenewswire.com

Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16
Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial

4 days ago · globenewswire.com

Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange

19 days ago · globenewswire.com

Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

26 days ago · globenewswire.com

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting

29 days ago · globenewswire.com

Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
Alpha Tau to Participate in October Investor Conferences

1 month ago · globenewswire.com

Alpha Tau to Participate in October Investor Conferences
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More

2 months ago · seekingalpha.com

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough

2 months ago · seekingalpha.com

Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough

Earnings

Next Earnings
Nov 19, 2026
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$16.00
Upside
+33.67%
Buy (5)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.